 A meta-analysis of 11 studies involving 7,695 HCC patients undergoing liver transplantation found that SRL-based immunosuppression is safe and effective in improving survival, reducing recurrence and mortality for HCC patients following LT. This article was authored by Shihua John, Li Xianli, Ping Li, and others.